Development and maintenance of penile erection requires the relaxation of the smooth muscle cells in the cavernous bodies and is essentially mediated by nitric oxide (NO). The penile flaccid state is conversely maintained by the alpha adrenergic neuroeffector system and by other vasoconstrictors, such as endothelin-1 (ET-1). In this study we examined the mechanisms involved in yohimbine-induced relaxation in human and rabbit corpora cavernosa (CC). We essentially found that yohimbine not only blocks contractions induced by adrenergic agonists, but also by non-adrenergic substances, such as ET-1. This effect was unrelated to antagonism at the level of ET receptors, because yohimbine did not affect ET-1-induced increase in intracellular calcium in isolated CC cells. Conversely, our data suggest that yohimbine counteracts ET-1-induced contractions by interfering with NO release from the endothelium. In fact, yohimbine-induced CC relaxation was inhibited by the mechanical removing of the endothelium and by blocking NO formation or signalling via guanylate cyclase and cGMP formation. Conversely, yohimbine activity was strongly increased by inhibiting cGMP degradation. In an experimental model of hypogonadism, performed on rabbits by chronic treatment with a long-lasting GnRH agonist, the relaxant yohimbine activity was also decreased, but completely restored by androgen supplementation. This effect was evident only in preparations in which the main source of NO was present (endothelium) or in which NO formation was not impaired by L-NAME. Our data indicate that the relaxant effect of yohimbine is both endothelium and androgen-dependent. This might justify the lack of efficacy of this drug in treatment of some form of organic erectile dysfunction.
Introduction
Penile erection is a physiological event controlled by two opposite drives. 1, 2 The first drive determines smooth muscle relaxation and an increase in cavernosal blood flow. The activity of this system is essentially mediated by the nitrergic network. 3 The second drive, operating for the majority of time, determines smooth muscle contraction and detumescence and it is essentially controlled by the sympathetic outflow. In the past few years, the physiological role of the nitrergic network has been extensively studied. Results from these studies culminated recently in the development of compounds that increase the effect of nitrergic transmission, such as sildenafil. 4 However, little attention has been dedicated to the role of sympathetic outflow that, as a component of the general reaction to stress, might be detrimental for penile erection and sexual activity. The lack of attention is quite surprising. Indeed, although the majority of patients with erectile dysfunction (ED) have an organic etiology, such a dysfunction can be further exacerbated by the co-existence of stress and anxiety. 1 Since at least a part of the negative effect of stress on penile erection is mediated by interactions between catecholamines and a-adrenoceptors present in the corpus cavernosum, the use of a-adrenoceptor antagonists seems to be the most rational approach to overcome this problem. Indeed, since the early 1980s, the intracavernous administration of a-adrenoceptor antagonists was a breakthrough in the oral treatment of ED. 5, 6 Oral phentolamine was also promising, but the preparation never reached the market due to consistent side effects. 7 Up to now, yohimbine is the only world-wide available aadrenoceptor antagonist for the treatment of ED. Yohimbine is a indole alkaloid obtained either from the bark of the tree Pausinystalia yohimbe or from the root of Rauwolfia, which has been known as an aphrodisiac compound since before the turn of the last century. Yohimbine was introduced in the treatment of erectile dysfunction more than 70 y ago. 8 A recent meta-analysis of all double-blind, randomised, placebo-controlled trials found a significant improvement in patients treated with yohimbine (odds ratio 3.85, confidence interval 2.22 -6.67%). 9 Nevertheless, up to now, there is the general impression that yohimbine can be useful in patients with ED, but with limited benefit and that it should be probably reserved for patients with a psychogenic ED. 10 -12 Reasons for the limited popularity of yohimbine might reside: (a) in its lack of patentability and commercial appeal; (b) in its unfavourable pharmacokinetic profile after oral administration; or (c) in its still unknown mechanism of action. 10, 13 Although several pharmacological properties of yohimbine have been described, the best documented activity of yohimbine was the antagonism at the a 2 -adrenoceptor. 14 Current hypotheses on the beneficial mechanism of action of yohimbine on sexual activity mainly point to a central mechanism of action of the drug. 15 -17 This suggestion is based chiefly upon results from animal studies showing the yohimbine increases sexual motivation even in sexually exhausted rats, due to its action on central a 2 -adrenoceptors located in the locus coeruleus. 18 -21 However this hypothesis is not completely convincing, because, when tested, yohimbine did not ameliorate sexual desire or thoughts in clinical studies. 15,22 -23 In addition, the blockade of a 2 -adrenoceptors is able not only to induce an enhancement of sympathetic outflow from the central nervous system but also an increase in catecholamine release from peripheral sympathetic nerve terminals. 24 -25 The latter could be detrimental for penile erection because human corporal smooth muscle is endowed with postsynaptic aadrenoceptors which predominantly belong to the a 1 subtype and mediate cellular contraction. 2,26 -28 An alternative hypothesis is that yohimbine also acts at a peripheral level, blocking a-adrenoceptors. Indeed, recent evidences obtained by binding and functional studies suggest that not only the a 1 but also a 2 -adrenoceptors mediating contractility are present in human and rabbit corpora cavernosa and that yohimbine might interact with both. 2,29 -31 Hence, it is possible that the positive effect of yohimbine on penile erection is not only related to its central effect but also to a peripheral sympatholytic activity. 32 Accordingly, intracavernosal administration of 0.5 and 1 mg of yohimbine in anaesthetised rabbits induced a transient but consistent increase in intracavernosal pressure approaching maximal vasodilatation. 32 Finally, there is evidence that yohimbine might also relax corpora cavernosa (cc) with a non-adrenergic mechanism. In fact, in both rabbit and human CC, yohimbine antagonises the effect of a potent, non-adrenergic, contractor for erectile smooth muscle tissue, endothelin-1 (ET-1). 32 Also phentolamine, an a 1 and a 2 -adrenoceptor antagonist for rabbit and human CC, blocks endothelin-1 (ET-1) induced contractility. 33 This non-adrenergic effect of phentolamine was dependent on the integrity of the endothelium and mediated by nitric oxide (NO) synthase activation. 33 The aim of the present study was to investigate the biochemical and physiological mechanisms underlying the penile relaxant effect of yohimbine, using rabbit and human isolated preparations of erectile tissue. Experiments have been performed in the presence or absence of endothelium, utilizing pharmacological tools, which interfere with NO formation and action as well as after androgen ablation and substitution. This experimental model has been designed on the basis of recent evidence indicating that androgens act at the penile level regulating NO formation and a-adrenergic responsiveness. 34, 35 Materials and methods
Corpus cavernosum preparations
Rabbit corpora cavernosa were obtained from New Zealand White rabbits (weighing approximately 3 kg). The animals were killed by a lethal dose of pentobarbital; then the penis was removed and the corpora cavernosa were carefully dissected free from the tunica albuginea and cut into three to four strips (0.260.260.7 cm).
Human corpora cavernosa were obtained from impotent men at the time of penile prosthesis implantation (n ¼ 7). After surgery, biopsy specimens of corpus cavernosum were immediately placed in cold Krebs solution and transported to the laboratory for in vitro experiments.
Human and rabbit strips were vertically mounted under 1.8 g resting tension in organ chambers containing 10 ml Krebs solution at 37 C, gassed with 95% O 2 and 5% CO 2 at pH 7.4. The solution had the following composition (mM): NaCl 118, KCl 4.7, KH 2 PO 4 1.2, MgSO 4 1.2, NaHCO 3 2.5, CaCl 2 2.5, glucose 10. The preparations were allowed to equilibrate for at least 90 min, during this period the bath medium was replaced every 15 min. Changes in isometric tension were recorded on a chart polygraph. To evaluate the drug-induced vasorelaxant effect, the preparation was precontracted with concentrations of endothelin-1 (ET-1; 0.1 -0.3 mM) or of Phe (100 mM) that were able to induce a vasoconstrictor response of a similar degree. The increase recorded in the presence of different concentrations of these agonists was expressed as percentage of maximal KCl Yohimbine and corpora cavernosa S Filippi et al (80 mM) -induced response taken as 100%. The high potassium salt solution was made by equimolar substitution of sodium by potassium. The presence of functional endothelium was assessed by testing the vasodilator effect of acetylcholine (ACh); the preparations in which ACh (1 mM) reduced the tone by less than 40% were not used for the study. To remove endothelium, strips of corpus cavernosum were rubbed between the thumb and index finger for $ 20 s. 36 The lack of a relaxation response to ACh in preconstricted preparations indicated that the procedure was successful. Experiments were carried out in corporal smooth muscle pre-contracted with a concentration of ET-1 (0.1 mm) able to produce an increase in tension of about 1200 mg; this value was taken as 100% and the relaxant effect induced by different yohimbine concentrations was referred to this value. Drug cumulative concentrations were added, at 7 min intervals, to the bath in order to obtain a concentration -relaxant effect curve; a 15 -30-min pre-treatment with selected antagonists and=or inhibitors was performed before repeating the concentrationresponse curve for yohimbine.
Cell cultures
Human corpora cavernosa (hCC) cells were prepared from corpus cavernosum samples obtained from two patients undergoing surgical correction for congenital curvature of the penis. Approval for the use of human material was given by the Local Ethical Committee. Briefly, tissues were mechanically dispersed and treated with 1 mg=ml bacterial collagenase for 15 min at 37 C. Fragments were then collected, washed in PBS and cultured in a mixture 1:1 (vol=vol) of Dulbecco's modified Eagle's medium and F-12 Ham (DMEM=F-12 1:1 Mix) supplemented with 10% heat-inactivated FBS, 2 mM glutamine, 100 U=ml penicillin and 100 mg=ml streptomycin and enriched with a mixture of insulin=transfer-ransferrin=selenium, in a fully humidified atmosphere of 95% air and 5% CO 2 . Cells began to emerge within 24 -48 h and were used within the second passage.
RT-PCR
Total RNA (500 ng) were retrotranscribed and then amplified using the Superscript One Step RT-PCR kit (Life Technologies, Milan, Italy). Specific oligonucleotidies primers for ET-1, ET A and ET B mRNA were purchased from Roche (Milan, Italy). The sequences of primers for ET-1 were: 5 0 -ATG GAT TAT TTG CTC ATG ATT TT-3 0 (sense) and 5 0 -CAG TCT TTC TCC ATA ATG TCT TCA GC-3 0 (antisense). 37 The sequences of primers for ET A were: 5 0 -CCT TTT GAT CAC AAT GAC TTT-3 0 (sense) and 5 0 -TTT GAT GTG GCA TTG AGC ATA CAG-3 0 (antisense). 38 The sequences of primers for ET B were: 5 0 -GGA CCC ATC GAG ATC AAG G-3 0 (sense) and 5 0 -AGA ATC CTG CTG AGG TGA AGG-3 0 (antisense). 39 The contamination of genomic DNA 
Measurement of intracellular calcium concentration
For intracellular calcium measurements, cells from human adult corpora cavernosa were grown in F-12
Ham to 70 -80% confluence on plastic coverslips (Aclar; Allied Engineering Plastic, Pottsville, PA). During the 24 h before the experiments, cells were maintained in serum-free medium. [Ca 2þ ] i was determined using the calcium-sensitive dye Fura-2=AM as described previously. 41 Briefly, cells were loaded with 4 mM Fura-2=AM for 45 min at 37 C, washed and incubated in Fura-2-free medium for another 20 min and finally resuspended in KrebsHenseleit HEPES-KHH buffer (1.25 mM CaCl 2 , 5.36 mM KCl, 0.81 mM MgSO 4 , 130.62 mM NaCl, 5.55 mM, glucose, 8.60 mM HEPES sodium salt, 11.7 mM HEPES free acid, 0.1% BSA, pH 7.4). Coverslips were then mounted diagonally in a quartz cuvette so that the excitation and emission path were at a 45 angle to the coverslip and stimuli were added directly to the cuvette. Fluorescence was measured by a spectrofluorimeter (LS50B, Perkin-Elmer) using a single-wavelength excitation: emission=340 : 510 nm. Calibration was performed using ionomycin (8 mM) to obtain F max followed by EGTA (10 mM, pH 10) to obtain F min . Fluorescence measurements were converted to [Ca 2þ ] i according to Grynkiewicz assuming a dissociation constant of Fura-2 for calcium of 224 nM. 42 
Experimental hypogonadism and androgen replacement
The study was approved by the Local Ethical Committee for Investigations in Humans of the University of Florence. New Zealand White male rabbits (weighing approximately 3 kg, n ¼ 12) were divided into three groups. One group was kept intact (controls, n ¼ 3). The remaining groups of animals were treated with a single administration of 2.9 mg=kg of the long-acting GnRH analog triptorelin pamoate (n ¼ 3) or vehicle (n ¼ 3). After 15 days a subset of GnRH treated rabbits (n ¼ 3) were supplemented with a pharmacological dose of testosterone enanthate (T, 30 mg=kg weekly). After 2 months of triptorelin pamoate administration and after 1 week from the last supplementation of Testosterone, rabbits were killed and blood was taken from the heart for testosterone measurement. open symbols, n ¼ 6 in four separate experiments) corpora cavernosa pre-contracted with ET-1 (0.1 mM, circles) and phenylephrine (Phe, 100 mM, squares). The increase in tone induced by the two agonists before addition of yohimbine was taken as 100% response and the effect of the drug was evaluated as per cent inhibition of this response. Means AE s.e.m; *P < 0.05 vs the same concentration of yohimbine in preparations pre-contracted with the different agonist. Note that at low yohimbine concentrations (0.3 -10 mM) was as potent as or even more potent in relaxing ET-1 than Phe pre-contracted strips.
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Measurement of testosterone
Plasma levels of testosterone were measured with an Automated Chemiluminescence System (Bayer Diagnostics, East Walpole, MA, USA), after appropriate extraction. Samples were mixed with four volumes of diethyl ether for 15 min, centrifuged for 5 min at 2000 rpm, and the aqueous phase was frozen in dry ice. The organic phase was recovered, evaporated to dryness under a nitrogen stream and reconstituted in the assay buffer.
Statistical analysis
Results are expressed as means AE s.e.m. for n experiments. Statistical analysis were performed with the Student's t-test for paired or unpaired data, with analysis of variance followed by least difference significance (LDS) test in order to evaluate the differences between groups, P < 0.05 was taken as significant. 
Results

Effect of exogenous different agonists on corpus cavernosum
The exposure of rabbit and human CC preparations to increasing concentrations of phenylephrine (Phe, 0.01 -300 mM), a specific a 1 -adrenoceptor agonist, and endothelin-1 (ET-1, 0.001 -0.3 mM) induced a dose-dependent contractile response characterised by similar E max but different EC 50 . Indeed, the EC 50 for Phe was 9.00 AE 0.06 mM and for ET-1 was 30.00 AE 0.02 nM in rabbit CC (Figure 1a , n ¼ 8 in six different animals). In human CC, the EC 50 for Phe was 8.00 AE 0.04 mM and for ET-1 it was 20.00 AE 0.04 nM (Figure 1b , n ¼ 6 in five patients).
Effect of yohimbine on pre-contracted corpus cavernosum
As shown in Figure 2a , increasing concentrations of yohimbine relaxes rabbit Phe (100 mM) or ET-1 (0.1 mM) pre-contracted preparations almost completely, with IC 50 ¼ 14 AE 0.04 mM and 2.10 AE 0.03 mM, respectively (n ¼ 8, obtained in six animals).
Although yohimbine, at lower concentrations, was even more potent in ET-1 than Phe pre-contracted rabbit strips, the maximal yohimbine-induced relaxation was lower in strips pre-contracted with ET-1 than with Phe (E max ¼ 70.00 AE 5.1%, vs 100.00 AE 0%, P < 0.01). Similar results were obtained in human CC (Figure 2b ). The relative IC 50 were 2 AE 0.15 mM for Phe and 0.70 AE 0.13 mM for ET-1. Maximum relaxation obtained with 100 mM Yohimbine and corpora cavernosa S Filippi et al yohimbine was 93.9 AE 8.00% for Phe and 83.30 AE 3.00% for ET-1 (Figure 2b , n ¼ 6, obtained in four patients).
Effect of yohimbine on isolated human corpus cavernosum cells
The relaxant effect of yohimbine on Phe precontracted CC strips is not surprising because it is well known that it antagonises a-adrenoceptor signalling, acting at the receptor level. 2 However, it is unclear how yohimbine does interfere with ET-1 signalling. We first hypothesised that yohimbine directly interacts with ET-1 receptors present in the CC. We tested this hypothesis in two preparations of human CC (hCC) stromal cells. As shown in Figure  3 
Effect of yohimbine on endothelium-deprived corpus cavernosum and on the NO pathway
To examine whether the presence of endothelium was essential for the functional antagonism of yohimbine on ET-1-induced CC contractility we repeated experiments in endothelium-deprived rabbit CC. We found that without endothelium, the inhibitory dose -response curve for yohimbine was reduced and significantly shifted to the right ( Figure  5a and b, middle panel, n ¼ 6, obtained in five animals). Similar results were obtained in intact rabbit CC strips by inhibiting the nitric oxide synthase with the reversible nitric oxide synthase inhibitor, N W -nitro-l-arginine-methyl-ester (L-NAME). Indeed, in the presence of L-NAME (100 mM, Figure 5a and b, lower panel) the yohimbine-induced CC relaxation was also reduced and shifted to the right (n ¼ 7, obtained in six animals). Similar results were obtained with 1 mM L-NAME. Conversely, the relaxant response to yohimbine was not influenced by a pre-treatment of the preparations with the cyclo-oxygenase inhibitor indomethacin (3 mM, data not shown). It is noteworthy that the concentrations of L-NAME and indomethacin used Yohimbine and corpora cavernosa S Filippi et al in these experiments were not able to significantly change the baseline tone of the preparations. In order to test whether or not the relaxation induced by yohimbine was due to NO production followed by soluble guanylate cyclase activation, experiments were carried out in the presence of either the potent and selective guanylate cyclase inhibitor ODQ or the cGMP-specific PDE 5 inhibitor, sildenafil. 4, 44 Inhibition of soluble guanylyl cyclase by addition of ODQ (1 mM) reduced, while sildenafil (0.3 mM) strongly increased, the yohimbine-induced relaxation in ET-1 pre-contracted rabbit (Figure 6a and b) and human (Figure 7a and b) CC preparations. Indeed, in the presence of the guanylate cyclase inhibitor, the dose -response curve for yohimbine was substantially shifted to the right and the maximal relaxation obtained (100 mM) was 35.00 AE 5.50% in rabbit strips and just 11.10 AE 4.60% in human strips as compared to their relative controls (n ¼ 9, obtained in seven animals; and n ¼ 6, obtained in three patients, respectively). On the contrary, the relaxant response to yohimbine was significantly enhanced and shifted to the left by 0.3 mM sildenafil in both rabbit (Figure 6a , n ¼ 7, obtained in five animals) and human preparations (Figure 7a , n ¼ 4, obtained in three patients). Figure 5 (a) Relaxant effect of increasing concentrations of yohimbine in rabbit corpora cavernosa pre-contracted by ET-1 (0.1 mM) in the presence (closed circles, n ¼ 10 in eight separate experiments) or not (closed triangles, n ¼ 6 in five separate experiments) of an intact endothelium or after L-NAME pre-treatment (100 mM, closed squares, n ¼ 7 in six separate experiments). The increase in tone induced by ET-1 before addition of yohimbine was taken as 100% response and the effect of the drug was evaluated as per cent inhibition of this response. Means AE s.e.m. *P < 0.05 and **P < 0.01 vs control curve (closed circles). (b) Typical experiment showing the relaxant effect induced by increasing concentrations of yohimbine in rabbit corpus cavernosum preparations pre-contracted with ET-1 (0.1 mM) in the presence (upper tracing) or not (middle tracing) of an intact endothelium or after L-NAME (100 mM) pre-treatment (lower tracing). The effect of ACh (1 mM; control for a functional endothelium) is shown in each tracing. Arrows indicate the addition of the substances.
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Effect of ET B antagonist on the relaxant response to yohimbine on corpus cavernosum
In order to test whether or not the relaxation induced by yohimbine was due to an ET B -mediated NO production, experiments were carried out in the presence of the potent and selective ET B receptor antagonist, BQ788. The dose -response curve for yohimbine was unaffected by 1 mM BQ788 either in rabbit (Figure 8a n ¼ 6, obtained in four animals) or human preparations (Figure 8b , n ¼ 4, obtained in three patients). This indicates that ET B receptors are not involved in the yohimbine-induced relaxation.
Effect of androgen deprivation on yohimbineinduced relaxation of rabbit corpus cavernous
A single administration of the long-acting GnRH analog triptorelin palmate (2.9 mg=kg) induces Figure 6 (a) Relaxant effect of increasing concentrations of yohimbine in rabbit corpora cavernosa pre-contracted by ET-1 (0.1 mM) alone (closed circles, n ¼ 10 in eight separate experiments) or in presence of ODQ (1 mM, closed squares, n ¼ 9 in seven separate experiments) and sildenafil (0.3 mM, closed triangles, n ¼ 7 in five experiments). ODQ significantly shifted to the right, and sildenafil to the left, yohimbine curves. The increase in tone induced by ET-1 before addition of yohimbine was taken as 100% response and the effect of the drug was evaluated as per cent inhibition of this response. Means AE s.e.m. *P < 0.05 and **P < 0.01 vs control curve (closed circles). (b) Typical experiment showing the relaxant effect induced by increasing concentrations of yohimbine in rabbit corpus cavernosum preparations pre-contracted by ET-1 (0.1 mM) alone (upper tracing) and in the presence (middle tracing) of ODQ (1 mM) or sildenafil (0.3 mM, lower tracing). The effect of Ach (1 mM; control for a functional endothelium) is shown in each tracing. Arrows indicate the addition of the substances.
Yohimbine and corpora cavernosa S Filippi et al hypogonadism in the treated rabbits. Indeed, 2 months after GnRH administration we observed a significant decrease (P < 0.01) in testosterone plasma levels, when compared to untreated or vehicletreated rabbits. Weekly administration of testosterone enanthate (T, 30 mg=kg weekly, n ¼ 3) to hypogonadal rabbits restored testosterone plasma levels to values not statistically different from controls (Table 1) . According to a previous study, chronic hypogonadism reduces the responsiveness to Phe, while testosterone administration restores it. 45 In untreated or vehicle-treated rabbits the percentage of maximal (KCI-induced) contraction obtained with Phe (100 mM) was 157.90 AE 12.70% and 150.20 AE 12.80%, respectively. Responsiveness to Phe was significantly reduced in the hypogonadal rabbits and completely restored in the T-treated hypogonadal rabbits ( Table 2 ). The relaxant effect of yohimbine on ET-1 pre-contracted corpora cavernosa was also different, according to the different androgen exposure (Figure 9a ). Hypogonadism significantly (P < 0.05) shifted the yohimbine doseresponse curve to the right (IC 50 ¼ 8.00 AE 0.04 mM, n ¼ 4, obtained in three animals), when compared to Yohimbine and corpora cavernosa S Filippi et al dose -response curves obtained in control (IC 50 ¼ 1.20 AE 0.04 mM, n ¼ 4, obtained in three animals) or vehicle-treated (IC 50 ¼ 1.50 AE 0.07 mM, n ¼ 4, obtained in three animals) rabbits. T supplementation to hypogonadal rabbit not only restored the normal sensitivity of corpora cavernosa to the relaxant effect of yohimbine (IC 50 ¼ 2.00 AE 0.05 mM, n ¼ 4, obtained in three animals), but even increased its maximal effect. Indeed 100 mM of yohimbine induced a 75.00 AE 1.50% of relaxation in control and 73.60 AE 8.00% in vehicle-treated rabbits, while in Ttreated hypogonadal rabbits the relaxation was almost maximal (96.00 AE 3.00%). All these differences were not present in endothelium-deprived corpora cavernosa or in L-NAME (100 mM) pretreated preparations (Figure 9b and 9c, n ¼ 4, obtained in three animals).
Discussion
In this study we demonstrated for the first time that micromolar concentrations of yohimbine relaxes rabbit and human corpora cavernosa in an endothelium-dependent and androgen-dependent way.
It is important to note that the concentrations of yohimbine able to relax human corpora cavernosa 'in vitro' are rather similar to those measured 'in vivo' in the plasma of human subjects assuming therapeutic doses of the yohimbine tablets. 2,46 Yohimbine and corpora cavernosa S Filippi et al Hence, it is possible that the relaxant effect we described might at least partially underlie the therapeutic action of yohimbine in erectile dysfunction. Up to now, there is a general agreement on the positive effect of yohimbine on ED, however its clinical use is currently indicated only for the management of the milder, non-organic form of the disease. 9 -12 This assumption is essentially based on negative clinical trials employing yohimbine in patients with organic ED. 47, 48 Our experimental results partially justify this assumption. In fact, we found that the relaxant effect of yohimbine is strongly decreased by a functional or mechanical disruption of the endothelium or by an inadequate androgenization. In these experimental conditions the relaxant dose -response curves for yohimbine are consistently shifted to the right or even abolished. Therefore it is possible that in pathological conditions characterised by a low testicular production of testosterone (hypogonadism) or by an impaired endothelial function (diabetes, hypertension and atherosclerosis) the concentrations of yohimbine needed to relax the smooth muscle cells of the erectile tissue are several fold higher than those achieved after oral intake of customary doses of the medication. The relaxant effect of yohimbine in rabbit and human corpora cavernosa is not apparently due to antagonism at the a 2 adrenoceptor only. In fact yohimbine also blocks the contractions induced by non-adrenergic compounds as ET-1. 29 -32 Since yohimbine does not interfere with ET-1-induced [Ca 2þ i increase in isolated corpora cavernosa cells, it seems unlikely that it acts as an ET-1 antagonist at receptor level. Hence, it is possible that yohimbine releases other relaxant factors able to counteract the effect of contractile agents such as ET-1. In this study we provided evidence that one of these factors corresponds to NO. In fact, removing the main source of NO (endothelium), decreasing NO formation (L-NAME) or action (ODQ), strongly impaired yohimbine induced relaxation of ET-1 pre-contracted corpora cavernosa. In addition, blocking degradation of cGMP by sildenafil (and therefore increasing NO signalling) substantially amplified yohimbine activity. All these findings seem to suggest an involvement of NO in yohimbineinduced relaxation. Finding that sildenafil strongly increases the yohimbine-induced corpora cavernosa relaxation might have clinical implications, suggesting the combined use of the two drugs in patients affected by ED. As far as we know, no clinical trials have been reported until now using yohimbine and sildenafil, although a combination of yohimbine with agents that enhance the release of NO should enhance its therapeutic effect on ED. 49 The aforementioned hypothesis, that yohimbine allows penile erection not only by blocking a-adrenoceptors, but also by releasing NO from the endothelium, is also in agreement with . Panel (c) shows results obtained in intact preparations pre-treated with 100 mM L-NAME. Hypogonadism induced a lower responsiveness to yohimbine only in preparation not treated with L-NAME and with an intact endothelium. In these preparations, responsiveness to yohimbine was completely restored and even increased in testosterone enanthate-treated rabbits. The increase in tone induced by ET-1 before addition of yohimbine was taken as 100% response and the effect of the drug was evaluated as per cent inhibition of this response. Means AE s.e.m. *P < 0.05 and **P < 0.01 vs control curve (closed circles).
Yohimbine and corpora cavernosa S Filippi et al experimental results obtained in hypogonadal rabbits. We found that a chronic low androgen exposure decreased the responsiveness of corpora cavernosa to yohimbine and that this was completely counteracted by an adequate substitutive treatment with testosterone. Androgens have long been known to have a major stimulatory influence on male sexual behaviour and recently it has been demonstrated that they are essential in the maintenance of NO-mediated erectile activity. 35 In particular, androgens stimulate neuronal and endothelial NOS and increase the amount of NO produced by corpus cavernosum and penile arteries during erection. 35,50 -52 Therefore, it is possible to speculate that the lower responsiveness of corpora cavernosa to yohimbine in hypogonadal rabbits is due to a lower formation of NO, and that the androgen substitution, repristinating NO activity, allows a normal NO-dependent yohimbine relaxant activity. In fact, we found no effect of androgen deprivation or substitution on yohimbine activity in corpora cavernosa in which the main source of NO, the endothelium, was removed or NO formation was impaired.
In conclusion, our study indicates that, beside its central effect, yohimbine may act directly at the level of corpora cavernosa facilitating their relaxation (and therefore penile erection) by a dual mechanism: blocking adrenergic receptors and releasing relaxing substances as NO. The lower relaxant effect of yohimbine in corpora cavernosa characterized by a damaged endothelium or by an inadequate androgenization might justify the lower efficacy of the drug in patients with some type of organic ED.
